Avoid common mistakes on your manuscript.
1 Erratum to: Drugs (2017) 77:521–546 DOI 10.1007/s40265-017-0701-9
Page 539, Table 6 Janus Kinase Inhibitors in preclinical and early clinical development
The first row/entry which currently reads:
Drug | Specificity | Clinical Status | Diseases |
|---|---|---|---|
OP0155 [199] | JAK3 | Preclinical | Rat adjuvant induced arthritis |
Should read:
Drug | Specificity | Clinical Status | Diseases |
|---|---|---|---|
PF-06651600 [199] | JAK3 | Phase 2 (ClinicalTrials.gov. NCT02969044, NCT02974868, NCT02958865) | Rheumatoid arthritis, alopecia areata, ulcerative colitis |
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-017-0701-9.
Rights and permissions
About this article
Cite this article
Banerjee, S., Biehl, A., Gadina, M. et al. Erratum to: JAK–STAT Signaling as a _target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77, 1261 (2017). https://doi.org/10.1007/s40265-017-0772-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-017-0772-7